ABIOMED (ABMD) Releases Earnings Results, Beats Expectations By $0.06 EPS

ABIOMED (ABMD) reported quarterly earnings results on Tuesday, May-3-2016. The company said it had a profit of $0.24 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.06. Analysts had a consensus of $0.18. The company posted revenue of $94.00 million in the period, compared to analysts expectations of $90.46 million. The company’s revenue was up 39.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.24 EPS.

ABIOMED opened for trading at $97.61 and hit $100.77 on the upside on Monday, eventually ending the session at $99.26, with a gain of 2.18% or 2.12 points. The heightened volatility saw the trading volume jump to 8,98,845 shares. Company has a market cap of $4,212 M.

In a different news, on Apr 20, 2016, Dorothy E Puhy (director) sold 10,000 shares at $100.00 per share price. According to the SEC, on Apr 20, 2016, Andrew J Greenfield (VP Healthcare Solutions) sold 10,000 shares at $99.10 per share price. On Apr 15, 2016, Michael G Howley (VP, Global Sales & Marketing) sold 9,800 shares at $98.64 per share price, according to the Form-4 filing with the securities and exchange commission.

Abiomed Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company’s products include Impella 2.5 a percutaneous micro heart pump with an integrated motor and sensors; Impella CP which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000 a circulatory support system for the temporary support of acute heart failure patients in profound shock and Symphony a minimally invasive implantable cardiac assist device.


Leave a Reply

ABIOMED - Is it time to Sell?

Top Brokerage Firms are advising their investors on ABIOMED. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.